These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38685816)

  • 1. The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK.
    Vasiliadou I; Grose D; Wilson C; Thapa A; Donnelly O; Lee E; Leslie I; Karim M; Hartley A; Partridge S; Medlow K; De Boisanger J; Metcalf R; Williamson A; Haridass A; Noble D; Mactier K; Walter H; Ma N; De Winton E; Cohen J; Rayner L; Geropantas K; Jankowska P; Mason J; Moleron R; Laws K; Ulahannan D; Nallathambi C; Michaelidou A; Nallamilli S; Raouf S; Palmer K; Bienz M; Karet T; Khalique S; Paterson C; Harrington K; Bhide S; Kong A
    Int J Cancer; 2024 Sep; 155(5):883-893. PubMed ID: 38685816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
    Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D;
    Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival impact of sequential chemotherapy following pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma.
    Iwaki S; Kadowaki S; Honda K; Narita Y; Masuishi T; Taniguchi H; Ando M; Muro K; Sawabe M; Suzuki H; Nishikawa D; Beppu S; Terada H; Kishikawa T; Kawakita D; Hanai N
    Int J Clin Oncol; 2024 Jun; 29(6):764-770. PubMed ID: 38555323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
    Cirillo A; Marinelli D; Romeo U; Messineo D; De Felice F; De Vincentiis M; Valentini V; Mezi S; Valentini F; Vivona L; Chiavassa A; Cerbelli B; Santini D; Bossi P; Polimeni A; Marchetti P; Botticelli A
    BMC Cancer; 2024 Apr; 24(1):430. PubMed ID: 38589857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The UK Divide: Does Having a Pembrolizumab-Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab-Chemotherapy Combination in Scotland.
    Thapa A; Cowell A; Peters A; Noble DJ; James A; Lamb C; Grose D; Vohra S; Schipani S; Mactier K; Mackenzie J; Srinivasan D; Laws K; Moleron R; Niblock P; Soh FY; Paterson C; Wilson C
    Clin Oncol (R Coll Radiol); 2024 May; 36(5):287-299. PubMed ID: 38395634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study.
    Cho BC; Braña I; Cirauqui B; Aksoy S; Couture F; Hong RL; Miller WH; Chaves-Conde M; Teixeira M; Leopold L; Munteanu M; Ge JY; Swaby RF; Hughes BGM
    BMC Cancer; 2024 Jul; 23(Suppl 1):1254. PubMed ID: 39054467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.
    Emancipator K; Huang L; Aurora-Garg D; Bal T; Cohen EEW; Harrington K; Soulières D; Le Tourneau C; Licitra L; Burtness B; Swaby R
    Mod Pathol; 2021 Mar; 34(3):532-541. PubMed ID: 33239737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
    Machiels JP; Tao Y; Licitra L; Burtness B; Tahara M; Rischin D; Alves G; Lima IPF; Hughes BGM; Pointreau Y; Aksoy S; Laban S; Greil R; Burian M; Hetnał M; Delord JP; Mesía R; Taberna M; Waldron JN; Simon C; Grégoire V; Harrington KJ; Swaby RF; Zhang Y; Gumuscu B; Bidadi B; Siu LL;
    Lancet Oncol; 2024 May; 25(5):572-587. PubMed ID: 38561010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
    Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
    BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States.
    Borse RH; Ramakrishnan K; Gandhi J; Dhankhar P; Chirovsky D
    J Med Econ; 2022; 25(1):954-965. PubMed ID: 35765888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
    Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
    Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
    J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
    Lang Y; Dong D; Wu B
    Clin Drug Investig; 2020 Dec; 40(12):1137-1146. PubMed ID: 33095408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical outcome of pembrolizumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a single center, real world study in China.
    Fan Z; Hui R; Ju H; Wu Y; Ma X; Song H; Liu Y; Rui M; Geng X; Zhao M; Xin Y; Wei D; Ren G
    Front Oncol; 2024; 14():1360657. PubMed ID: 38440229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC).
    Sun L; Cohen RB; Dimitrios Colevas A
    Oral Oncol; 2024 Nov; 158():106997. PubMed ID: 39159526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab.
    Hagiwara K; Matsuki T; Okada T; Fushimi C; Kondo T; Takahashi H; Okamoto I; Tokashiki K; Hanyu K; Kishida T; Ito T; Yamashita G; Tsukahara K; Masubuchi T; Tada Y; Momiyama K; Yaguchi R; Oridate N; Omura GO; Yamashita T
    Anticancer Res; 2024 Sep; 44(9):4057-4072. PubMed ID: 39197913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis.
    Huang S; Huang Z; Huang X; Luo R; Liang W; Qin T
    Front Immunol; 2024; 15():1375136. PubMed ID: 39072325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world time on treatment with immuno-oncology therapy in recurrent/metastatic head and neck squamous cell carcinoma.
    Ramakrishnan K; Liu Z; Baxi S; Chandwani S; Joo S; Chirovsky D
    Future Oncol; 2021 Aug; 17(23):3037-3050. PubMed ID: 34044594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.